ARTICLE | Company News
Chiron, Enanta deal
May 23, 2005 7:00 AM UTC
CHIR granted Enanta exclusive rights to develop and commercialize its preclinical portfolio of HCV protease inhibitors. CHIR also granted a non-exclusive license to Enanta for its HCV technology to de...